Pelabresib Plus Ruxolitinib Improves Signs of Underlying Myelofibrosis Pathobiology and Provides Clinical Benefit Over JAK Inhibitor Monotherapy By Ogkologos - March 25, 2025 466 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the MANIFEST-2 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gemcitabine Intravesical System for Non-Muscle Invasive Bladder Cancer ESMO Calls for Robust EU Taxation of Tobacco Products, Aiming to Prevent Cancers Attributable to Tobacco Use EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim MOST POPULAR FDA Approves Treosulfan with Fludarabine As a Preparative Regimen for alloHSCT... March 13, 2025 105-Year-Old Woman Sets Record For 100-Meter Dash November 16, 2021 Genetic Counseling for Hereditary Breast Cancer: What People With a Family... October 26, 2023 Patients with Advanced Hodgkin’s Lymphoma Treated with Brentuximab Vedotin Plus AVD... July 19, 2022 Load more HOT NEWS New Research in Treating Non-Small Cell Lung Cancer: 2022 North America... Fosnetupitant Is Valuable in the Prophylaxis of Acute, Delayed, and Beyond... Tailored Psychotherapy Eases Depression in People with Advanced Cancer How Does Ovarian Cancer Form? A New Study Points to MicroRNA
